Here is the design of a clinical trial:

Official Title: A Mobile Supportive Care App for Patients With Metastatic Lung Cancer: a Pilot Randomized Controlled Trial - The Lung Cancer App (LuCApp) Study

Included conditions:
- Nonsmall Cell Lung Cancer
- Small Cell Lung Carcinoma

Study Armgroups:
- {'label': 'LuCApp + Standard Care', 'type': 'EXPERIMENTAL', 'description': 'LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.\n\nLuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met.', 'interventionNames': ['Other: The Lung Cancer App - LuCApp']}
- {'label': 'Standard Care', 'type': 'ACTIVE_COMPARATOR', 'description': 'Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.', 'interventionNames': ['Other: Standard care']}

Interventions:
- {'type': 'OTHER', 'name': 'The Lung Cancer App - LuCApp', 'description': 'The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care', 'armGroupLabels': ['LuCApp + Standard Care']}
- {'type': 'OTHER', 'name': 'Standard care', 'description': 'The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.', 'armGroupLabels': ['Standard Care']}

Primary Outcomes:
- {'measure': 'The primary outcome is the change in the score of the Trial Outcome Index (TOI) in the Functional Assessment of Cancer Therapy (Lung) questionnaire from baseline to 12 weeks.', 'description': 'FACT-L questionnaire contains four general and one lung cancer symptom-specific subscales. General subscales include: Physical Well-Being (PWB), Social/family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). The Lung Cancer Subscale (LCS) assesses symptoms commonly reported by lung cancer patients (e.g., shortness of breath; loss of weight; tightness in chest). The TOI is derived by adding scores on the PWB and FWB subscales to the LCS. Because they contain the most relevant questions about symptoms and physical functioning, the LCS and TOI were selected as the primary focus of this analysis.', 'timeFrame': '12 weeks'}

Please estimate the sample size based on the assumption: 
The study assumes a 20% attrition rate, 90% power, a two-sided significance level (α) of 0.05, and a pooled standard deviation (SD) of 15.
Sample size calculation
        The change in the Trial Outcome Index (TOI) of the FACT-L questionnaire from baseline to 12 weeks was used as primary endÂ point for this study. FACT-L questionnaire contains four general and one lung cancer symptom-specific subscales. General subscales include: Physical Well-Being (PWB), Social/family Well-Being, Emotional Well-Being and Functional Well-Being (FWB).42 The LCS assesses symptoms commonly reported by patients with lung cancer (eg, shortness of breath; loss of weight; tightness in chest). The TOI is derived by adding scores on the PWB and FWB subscales to the LCS. Because they contain the most relevant questions about symptoms and physical functioning, the LCS and TOI were selected as the primary focus of this analysis. All FACT-L questions are rated on 5-point Likert-type scales ranging from 0 (ânot at allâ) to 4 (âvery muchâ). TOI scores range from 0 to 84 where higher scores represent better HRQoL or fewer symptoms. After accounting for about 20% attrition rate, we estimated that with 120 patients allocated 1:1 between LuCApp and usual care groups, the study would have 90% power with a two-sided Î± of 0.05 to detect a significant between-group difference of 5 points43 in the change in the TOI score from baseline to 12 weeks, given a pooled SD of 15.44